{"transactions":[{"id":684494,"issuer":{"id":4033,"kind":"organization","name":"Legend Biotech Corp","symbol":"LEGN"},"owners":[{"id":22527,"kind":"person","name":"BASH ALAN","position":1,"cik":"0001908421","reported_name":"BASH ALAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Ordinary Shares","published_at":"2026-08-18T20:15:15.000Z","date":"2026-08-14","kind":"grant","planned":false,"acquired":true,"shares":4908,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares of the Issuer may be represented by American Depositary Shares (\"ADSs\"). Each ADS represents two ordinary shares of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted share units (the \"RSUs\"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 1/3 of the RSUs vest and becomes exercisable on each of July 27, 2027, July 27, 2028, and July 27, 2029, respectively, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":35142,"source":{"system":"sec-edgar","filing":"0001908421-26-000005","document":"form4-08182026_040805.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801198/000190842126000005/form4-08182026_040805.xml","form_type":"4"}},{"id":2250842,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":22527,"kind":"person","name":"BASH ALAN","position":1,"cik":"0001908421","reported_name":"BASH ALAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-31T09:59:08.000Z","date":"2022-05-31","kind":"disposition_to_issuer","acquired":false,"shares":575000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":2.99,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":575000},"source":{"system":"sec-edgar","filing":"0000899243-22-020075","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651431/000089924322020075/doc4.xml","form_type":"4"}},{"id":2359300,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":22527,"kind":"person","name":"BASH ALAN","position":1,"cik":"0001908421","reported_name":"BASH ALAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-02T16:10:21.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":575000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option shall vest 25% on the first anniversary of the grant date and in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continued service through such date."}],"balance_after":575000,"derivative":{"exercise_price":2.99,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":575000},"source":{"system":"sec-edgar","filing":"0000899243-22-008588","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651431/000089924322008588/doc4.xml","form_type":"4"}}]}